Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Conditions

• Diffuse Large B Cell Lymphoma
• Primary Mediastinal Lymphoma
• Mantle-Cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Advanced Solid Tumors

Interventions

• DRUG: Tazemetostat and [14C] Tazemetostat

Sponsor

Epizyme, Inc.